---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Repetitive transcranial magnetic stimulation"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Repetitive transcranial magnetic stimulation. Topics: CANMAT guideline: rTMS and theta burst protocols, VA/DoD guideline: rTMS after two or more pharmacologic trials, NICE interventional procedures guidance on rTMS, Pivotal sham-controlled trial of left prefrontal TMS, and 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/repetitive-transcranial-magnetic-stimulation"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Repetitive transcranial magnetic stimulation

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Repetitive Transcranial Magnetic Stimulation

<a id="topic-2.2.2.1.6-1"></a>

### CANMAT guideline: rTMS and theta burst protocols

> “Repetitive TMS shows efficacy for DTD, with response rates of 40% to 50%”
> “High-frequency (5 Hz or higher) rTMS delivered over the left dorsolateral prefrontal cortex (DLPFC) has the largest evidence base and is recommended as a first-line protocol, along with low-frequency (1 Hz or lower) rTMS delivered over the right DLPFC.”
> “TBS is recommended as a first-line protocol”
> “Accelerated iTBS to the left DLPFC has evidence for efficacy and a large RCT found no significant differences between accelerated bilateral TBS and high frequency rTMS.”
> “Unlike ECT, rTMS does not require anaesthesia and has no cognitive side effects.”
> “Finally, except in emergent situations as mentioned above, rTMS should generally be considered before ECT, given its less invasive nature and that individuals may continue to work or attend school while undergoing rTMS.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.6-2"></a>

### VA/DoD guideline: rTMS after two or more pharmacologic trials

> “For patients who have demonstrated partial or no response to two or more adequate pharmacologic treatment trials, we suggest offering repetitive transcranial magnetic stimulation for treatment.”
> “(Weak for | Reviewed, Amended)”
> “The NNT for response is between 3.4 and 9 patients, and the NNT for remission was between five and seven patients.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.6-3"></a>

### NICE interventional procedures guidance on rTMS

> “The evidence on repetitive transcranial magnetic stimulation for depression shows no major safety concerns.”
> “Repetitive transcranial magnetic stimulation for depression may be used with normal arrangements for clinical governance and audit.”

Source: [NICE (2015)](https://www.nice.org.uk/guidance/htg396/chapter/1-Recommendations)

<a id="topic-2.2.2.1.6-4"></a>

### Pivotal sham-controlled trial of left prefrontal TMS

> “In a double-blind, multisite study, 301 medication-free patients with major depression who had not benefited from prior treatment were randomized to active (n = 155) or sham TMS (n = 146) conditions.”
> “Remission rates were approximately twofold higher with active TMS at week 6 and significant on the MADRS and HAMD24 scales (but not the HAMD17 scale).”
> “Active TMS was well tolerated with a low dropout rate for adverse events (4.5%) that were generally mild and limited to transient scalp discomfort or pain.”

Source: [O'Reardon et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17573044/)

<a id="topic-2.2.2.1.6-5"></a>

### OPT-TMS: sham-controlled trial in antidepressant-free outpatients

> “Primary efficacy analysis revealed a significant effect of treatment on the proportion of remitters (14.1% active rTMS and 5.1% sham) (P = .02).”
> “The number needed to treat was 12. Most remitters had low antidepressant treatment resistance.”

Source: [George et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20439832/)

<a id="topic-2.2.2.1.6-6"></a>

### THREE-D: intermittent theta burst compared with 10 Hz rTMS

> “Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered in 3 min, versus 37·5 min for a standard 10 Hz treatment session.”
> “Between Sept 3, 2013, and Oct 3, 2016, we randomly allocated 205 participants to receive 10 Hz rTMS and 209 participants to receive iTBS.”
> “In patients with treatment-resistant depression, iTBS was non-inferior to 10 Hz rTMS for the treatment of depression.”
> “The most common treatment-related adverse event was headache in both groups (10 Hz rTMS: 131 [64%] of 204; iTBS: 136 [65%] of 208).”

Source: [Blumberger et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29726344/)

<a id="topic-2.2.2.1.6-7"></a>

### Network meta-analysis of non-surgical brain stimulation

> “113 trials (262 treatment arms) that randomised 6750 patients (mean age 47.9 years; 59% women) with major depressive disorder or bipolar depression met the inclusion criteria.”
> “low frequency right rTMS (3.65, 2.13 to 6.24), intermittent theta burst stimulation (3.20, 1.45 to 7.08), high frequency left rTMS (3.17, 2.29 to 4.37)”
> “All treatment strategies were at least as acceptable as sham therapy.”

Source: [Mutz et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6435996/)

<a id="topic-2.2.2.1.6-8"></a>

### Stanford neuromodulation therapy: FDA clearance

> “The Magnus Neuromodulation System with SAINT Technology is indicated for the treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.”
> “Regulation Name: Repetitive Transcranial Magnetic Stimulation System Regulatory Class: Class II”

Source: [FDA SAINT Neuromodulation System clearance (2022)](https://www.accessdata.fda.gov/cdrh_docs/pdf22/K220177.pdf)

<a id="topic-2.2.2.1.6-9"></a>

### Stanford neuromodulation therapy: initial sham-controlled trial

> “The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT).”
> “At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT.”
> “The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group.”

Source: [Cole et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34711062/)

<a id="topic-2.2.2.1.6-10"></a>

### Stanford neuromodulation therapy: confirmatory sham-controlled trial

> “In the current RCT, 53 participants with TRD were enrolled, and 48 who continued to meet entry criteria were randomized to receive active (N=24) or sham (N=24) SNT.”
> “At 1-month, remission (primary outcome) was achieved in 50.0% of active vs. 20.8% of sham participants”

Source: [Kratter et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805067/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
